Apyx Medical (APYX) Price to Sales (2011 - 2026)

Apyx Medical (APYX) has reported Price to Sales for 16 consecutive years, with 13.62 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Sales rose 82.16% year-over-year to 13.62; the trailing twelve-month figure through Jun 2026 stood at 3.24 (up 77.07% YoY), and the FY2025 full-year result was 2.77, up 122.94% from the prior year.
• Price to Sales rose to 13.62 in Q2 2026 per APYX's latest filing, from 12.37 in the prior quarter.
• Across five years, Price to Sales topped out at 19.64 in Q2 2022 and bottomed at 3.74 in Q3 2024.
• Historically, Price to Sales has averaged 9.27 across 5 years, with a median of 7.55 in 2025.
• The sharpest annual moves came in 2022 and 2026: Price to Sales tumbled 75.52% in 2022, then jumped 125.28% in 2026.
• Over 5 years, Price to Sales stood at 6.42 in 2022, then dropped by 3.57% to 6.19 in 2023, then tumbled by 32.18% to 4.2 in 2024, then jumped by 81.76% to 7.63 in 2025, then jumped by 78.47% to 13.62 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 13.62, 12.37, and 7.63 for Q2 2026, Q1 2026, and Q4 2025 respectively.